Technical Analysis for ADGI - Adagio Therapeutics, Inc.

Grade Last Price % Change Price Change
D 43.72 -6.46% -3.02
ADGI closed down 6.46 percent on Friday, September 24, 2021, on 45 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong N/A N/A Down
Historical ADGI trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
20 DMA Support Bullish -6.46%
1,2,3 Pullback Bullish Bullish Swing Setup -6.46%
NR7 Range Contraction -6.46%
NR7-2 Range Contraction -6.46%
Wide Bands Range Expansion -6.46%
1,2,3 Pullback Bullish Bullish Swing Setup -2.67%
Older End-of-Day Signals for ADGI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Outside Day about 18 hours ago
Fell Below Previous Day's Low about 18 hours ago
20 DMA Support about 18 hours ago
60 Minute Opening Range Breakdown about 18 hours ago
Fell Below 20 DMA about 18 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Adagio Therapeutics, Inc. Description

Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Immunology Immune System Infectious Diseases Antibodies Monoclonal Antibody Antibody Antibody Solutions Neutralizing Antibody

Is ADGI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 59.5
52 Week Low 20.5
Average Volume 658,441
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 43.89
10-Day Moving Average 48.47
Average True Range 5.43
ADX 51.84
+DI 26.03
-DI 15.71
Chandelier Exit (Long, 3 ATRs) 43.21
Chandelier Exit (Short, 3 ATRs) 43.16
Upper Bollinger Bands 58.79
Lower Bollinger Band 28.99
Percent B (%b) 0.49
BandWidth 67.90
MACD Line 5.51
MACD Signal Line 6.62
MACD Histogram -1.1099
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 50.73
Resistance 3 (R3) 51.10 49.14 49.56
Resistance 2 (R2) 49.14 47.36 48.95 49.17
Resistance 1 (R1) 46.43 46.25 45.45 46.06 48.78
Pivot Point 44.47 44.47 43.98 44.28 44.47
Support 1 (S1) 41.76 42.69 40.78 41.39 38.66
Support 2 (S2) 39.80 41.58 39.61 38.27
Support 3 (S3) 37.09 39.80 37.88
Support 4 (S4) 36.72